Danielle M. Brander, MD, Duke Cancer Institute

home / authors / danielle-m-brander-md-duke-cancer-institute

Articles

Relapsed/Refractory CLL Treatment: Addressing Unmet Needs

Relapsed/Refractory CLL Treatment: Addressing Unmet Needs

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
February 8th 2021

Read More

Frontline CLL Treatment: Addressing Unmet Needs

Frontline CLL Treatment: Addressing Unmet Needs

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

Allogeneic Transplantation for CLL

Allogeneic Transplantation for CLL

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

Relapsed/Refractory CLL: Repeat Molecular Testing

Relapsed/Refractory CLL: Repeat Molecular Testing

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

Therapeutic Sequencing in Relapsed/Refractory CLL

Therapeutic Sequencing in Relapsed/Refractory CLL

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

CLL Patient Management During COVID-19 and Telehealth

CLL Patient Management During COVID-19 and Telehealth

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

CLL Treatment Approaches During COVID-19

CLL Treatment Approaches During COVID-19

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

Frontline CLL: Treatment Algorithms

Frontline CLL: Treatment Algorithms

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

Minimal Residual Disease in CLL

Minimal Residual Disease in CLL

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

Frontline CLL Treatment With Fixed-Duration Regimens

Frontline CLL Treatment With Fixed-Duration Regimens

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

Anti-BCL2/CD20 Combination Therapy for Frontline CLL

Anti-BCL2/CD20 Combination Therapy for Frontline CLL

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

Anti-CD20/BTKi Therapy for Frontline CLL

Anti-CD20/BTKi Therapy for Frontline CLL

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

BTK Monotherapy for Frontline CLL

BTK Monotherapy for Frontline CLL

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

Selecting Frontline Therapy to Treat CLL

Selecting Frontline Therapy to Treat CLL

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Catherine C. Coombs, MD, UNC School of Medicine;Danielle M. Brander, MD, Duke Cancer Institute
January 8th 2021

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need